Amarin Corp Plc (AMRN)

[bidmark]

I think we all suffer from the “it’ll sell itself” hype that several posters promoted for years. In the Piper Sandler chat, Yasmin asked Karim about the difference between launching in the USA vs. Europe. The main difference, he explained, is that Vascepa had been around for a number of years in the US and in Europe it was pretty much unknown - so marketing a new indication vs. a new start. She didn’t ask him which he preferred!